Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

Schlieren (Zurich), Switzerland, May 24, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today results from a placebo-controlled, double-blind combined phase I/IIa study with CYT007-TNFQb, a novel vaccine candidate for the treatment of psoriasis and other inflammatory conditions. The present study was a first-time-in-man clinical trial and included 48 patients suffering from moderate to severe plaque psoriasis. In a first part of the study, the safety and tolerability of ascending doses of CYT007-TNFQb were assessed in 24 patients. In the following second part of the study, the exploratory efficacy of the highest vaccine dose was compared to placebo in another 24 patients.

All doses of CYT007-TNFQb tested were safe and well tolerated. All the patients who received the vaccine mounted an antibody response against TNF-?. Exploratory efficacy was assessed according to the Psoriasis Area and Severity Index (PASI), a commonly used measure to evaluate the disease severity in psoriatic patients. The graph below shows the course of the PASI scores throughout the study period (i.e. from baseline up to week 16) for the CYT007-TNFQb-treated and the placebo group.


SEE ATTACHMENT FOR CHART

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented the study results: “The prime objective of this first-time-in-man clinical trial was to demonstrate safety and tolerability of this novel vaccine candidate. This objective was clearly reached. With regard to efficacy we are seeing a temporary improvement of the disease. We will now in detail analyse a broad set of biochemical markers in order to determine whether this observed improvement of disease is indeed treatment related. This additional analytical and laboratory work, which will take several months to complete, will then guide us in the further development of this novel vaccine candidate.”

Cytos Biotechnology will discuss the development program for CYT007-TNFQb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 30 Reportlinker.com announces that a new market ... Drug Patent Inventor Report 2010 ... Report profiles the individuals, US states, and countries leading pharmaceutical ... to 2009, this report provides complete lists of: ...
... (Nasdaq: CLSN ), a leading oncology drug ... patients enrolled in its pivotal Phase III ThermoDox ® ... the Data Monitoring Committee (DMC) has unanimously recommended that ... of reaching the 600 patients required to complete the ...
Cached Medicine Technology:Reportlinker Adds Drug Patent Inventor Report 2010 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 3Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 4
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... 2014 As reported by the ... 7/11/14), a significant number of severe adverse events such ... and even death from the highly-promoted and costly immune-system ... Times report , a regulatory filing revealed that ... patients was almost 14% of prescriptions, up from 9.1% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... many human beings. A new Mayo Clinic study reveals the ... definition of contact dermatitis is that it is a skin ... direct contact with an allergen. ,The ten allergens ... ,? Nickel (nickel sulfate hexahydrate ,? Gold (gold sodium ...
... data on men's health over the last two decades. The ... a semi annual survey.// Judging by the response, the Harvard ... on how men can maintain a satisfying sex life, as ... most prevalent illness in elderly men followed by chronic illnesses ...
... Mumbai were crippled as the striking doctors were determined to ... All the government hospitals in Mumbai suffered due to absence ... 15 government-managed hospitals in this bustling city of over 15 ... demanding better security while on the job after relatives of ...
... Cyriac Joseph has expressed the need for quality medical ... not leave any stone unturned to weed out black ... this is a matter of grave concern to the ... The educationists, professionals, governments and all the stakeholders in ...
... from Duke university Medical Center have established that ... influenced by a complex interplay between genetic and ... crucial role in determining the psychological and biological ... results of four such studies that examined the ...
... that the much dreaded bird flu virus may be carried across ... the potential of posing a serious health hazard, specifically in the ... bird flu viral strain. ,The exact mechanism of how ... if bird flu virus is found in birds in U.K, it ...
Cached Medicine News:Health News:Health Services Came To A Halt As Mumbai Doctors Strike Continues 2Health News:Genes And Environmental Factors Determine Stress Response 2
Curved shafts with 2.0 mm wide serrated tips and 0.4 mm pin in upper jaw. Serrated cross action handle with dull finish....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
Biconvex jaw design. 40 degree angled shafts. Tip to angle length: 7.5 mm. Locking handle. Manufacturing in titanium....
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Medicine Products: